Q4 2019
Released Mar 13, 2020, before the open
10-K filed Mar 13, 2020, 73 days after period end · 0001104659-20-032764
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derived— vs Q4 2018−100.0% vs Q3 2019
Net Income-$3.29M-$3.29M derivedN/M vs Q4 2018N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$3,448,251N/M
Operating Cash Flowderived-$3,308,042N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2019dderived from reported figures | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — |
| Net Income | -$3.29M | -$3.23M | -$5.33M | -$2.97M |
| EPS Diluted | — | -$0.15 | -$0.25 | -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR